Déjà vu bei Amarillo... - 500 Beiträge pro Seite
eröffnet am 27.11.06 10:55:38 von
neuester Beitrag 06.03.07 00:42:14 von
neuester Beitrag 06.03.07 00:42:14 von
Beiträge: 22
ID: 1.096.740
ID: 1.096.740
Aufrufe heute: 0
Gesamt: 2.456
Gesamt: 2.456
Aktive User: 0
ISIN: US02301P1066 · WKN: 917640
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5100 | +134,48 | |
| 0,7000 | +75,00 | |
| 2,25 | +63,04 | |
| 15,348 | +19,53 | |
| 0,5800 | +16,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8209 | -22,56 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 | |
| 5,0100 | -90,93 |
Feedback
Und einen habe ich noch für heute... schaut euch mal Amarillo Bio. an... heut überragende News und Empfehlung!!! Da könnte es schnell wieder auf alte Höhen gehen...
Hier die Empfehlung: http://www.wallstreet-online.de/adserver/code.php?bid=10010
und die News...
http://www.wallstreet-online.de/nachrichten/nachricht/197484…
Hier die Empfehlung: http://www.wallstreet-online.de/adserver/code.php?bid=10010
und die News...
http://www.wallstreet-online.de/nachrichten/nachricht/197484…
Antwort auf Beitrag Nr.: 25.742.121 von RiseTrade am 27.11.06 10:55:38Das ist der Hammer, oder? Erinnert mich ganz stark an die Zeit Jan - März 2006, da ist das Ding auch von unter 0,40 auf 1,40 gestiegen.
Hier ist übrigens der Hauptthread:
Thread: AMARILLO - Super News und Empfehlung
Greetz
xTRADERx
Do your own DD!
Hier ist übrigens der Hauptthread:
Thread: AMARILLO - Super News und Empfehlung
Greetz
xTRADERx
Do your own DD!
Ja sieht gut asu bin auf die Amis gespannt!
Star Uranium heut auch höchst interessant....
http://www.goldinvest.de/public/data/documents/9010200611270…
http://www.goldinvest.de/public/data/documents/9010200611270…
Antwort auf Beitrag Nr.: 25.743.081 von RiseTrade am 27.11.06 12:14:23Habe eben den Ticker von Pearlsfactory über Amarillo gesehen und gelesen!
Mit dem neuen CHINA-Vertrag kommt ja echt ein unglaubliches Potential
in den Titel und das wir noch vor den Amis drinn sein können ist ja super.
Ich werde meine Position auf jeden Fall noch mal aufstocken auch wenn anscheinend die grosse Masse noch nicht so recht daran glaubt.
Mir soll's recht sein - mit den Amis kommt sicher nochmal richtig Schwung in die Bude
Mit dem neuen CHINA-Vertrag kommt ja echt ein unglaubliches Potential
in den Titel und das wir noch vor den Amis drinn sein können ist ja super.Ich werde meine Position auf jeden Fall noch mal aufstocken auch wenn anscheinend die grosse Masse noch nicht so recht daran glaubt.
Mir soll's recht sein - mit den Amis kommt sicher nochmal richtig Schwung in die Bude
Trading Spotlight
Amarillo, Texas and Taipei, Taiwan, 27. November 2006 ? Wie Amarillo Biosciences, Inc. (ABI) (OTC-BB: AMAR) heute bekannt gab, hat das Unternehmen mit CytoPharm, Inc., einem in Taipei ansässigen taiwanesischen Biopharma-Unternehmen, ein Lizenz- und Lieferabkommen unterzeichnet. Die Muttergesellschaft von CytoPharm, Vita Genomics, Inc., ist das größte Biotech-Unternehmen in Taiwan und spezialisiert auf Pharmakogenomik sowie klinische Forschung in bestimmten Bereichen.
Nach den Bestimmungen dieses Abkommenss werden CytoPharm und ihre Tochtergesellschaft alle klinischen Studien durchführen und in China sowie in Taiwan (Zielregion) die arzneimittelrechtliche Zulassung für das niedrigdosierte orale Interferon ("Low Dose Oral Interferon" ) von ABI in der Zielregion für die Indikationen Influenza und Hepatitis B (HBV) beantragen. Im Vorfeld zu klinischen Studien, die in 2007 fortgeführt werden, hat CytoPharm in den Zielregionen Gespräche mit den Arzneimittelbehörden aufgenommen.
Nach den Bestimmungen dieses Abkommenss werden CytoPharm und ihre Tochtergesellschaft alle klinischen Studien durchführen und in China sowie in Taiwan (Zielregion) die arzneimittelrechtliche Zulassung für das niedrigdosierte orale Interferon ("Low Dose Oral Interferon" ) von ABI in der Zielregion für die Indikationen Influenza und Hepatitis B (HBV) beantragen. Im Vorfeld zu klinischen Studien, die in 2007 fortgeführt werden, hat CytoPharm in den Zielregionen Gespräche mit den Arzneimittelbehörden aufgenommen.
Antwort auf Beitrag Nr.: 25.743.271 von RiseTrade am 27.11.06 12:28:36Langsam wirds mir aber etwas mulmig...0,85 EUR in Frankfurt...
wahnsinn
ich denke bei solchen kursen hätte der ticker eher so heissen müssen!
"Kursexplosion steht bevor...
Jetzt den Kursvorsprung nutzen!"
"Kursexplosion steht bevor...
Jetzt den Kursvorsprung nutzen!"
Antwort auf Beitrag Nr.: 25.743.801 von Spekulatius_28 am 27.11.06 13:07:06Der is gut! 
Aber heute morgen sah das ja auch noch alles viel gesünder aus und da hatten die Jungs schon Recht...der Report liest sich doch gar nicht so schlecht finde ich.
Greetz
xTRADERx
Do your own DD!
Aber heute morgen sah das ja auch noch alles viel gesünder aus und da hatten die Jungs schon Recht...der Report liest sich doch gar nicht so schlecht finde ich.
Greetz
xTRADERx
Do your own DD!
Kabooom... geile Empfehlung... bin gespannt auf die A.
geht richtig schön ab!
War letztes Jahr mal dabei, als stockreport die Aktie von Amarillo empfohlen hat.
Da hat sich die Aktie eine Woche oder länger konstant nach oben entwickelt.
ich befürchte Amarillo ist jetzt schon auf einigen short-watchlisten ganz oben auf der liste...
War letztes Jahr mal dabei, als stockreport die Aktie von Amarillo empfohlen hat.
Da hat sich die Aktie eine Woche oder länger konstant nach oben entwickelt.
ich befürchte Amarillo ist jetzt schon auf einigen short-watchlisten ganz oben auf der liste...
Antwort auf Beitrag Nr.: 25.744.749 von NextLevelTrader am 27.11.06 14:18:56vom kurs her schon, aber ich denke dafür ist das volumen (noch?) zu gering.
Greetz
xTRADERx
Do your own DD!
Greetz
xTRADERx
Do your own DD!
Antwort auf Beitrag Nr.: 25.744.749 von NextLevelTrader am 27.11.06 14:18:56Glaub ich noch net... Des interesse fehlt dafür... "noch"
Auch bei den AMIS gibt's heute ne Empfehlung. Vom Stewart Report. Hier der Originaltext (hab ich auch schon im Hauptthread geposted):
Amarillo Biosciences (NASDAQ/BB: AMAR): $0.63
Those of you who prefer the HotLine audio version over the e-mail transcript may have noticed that there was no recording to correspond with the Interim Special Report featuring ICRD. This was intentional. Since the Report was not scheduled, no one would have known to call. Moreover, I felt that the information from the Oct. 25 recording featuring Amarillo Biosciences held a good deal of value, so I wanted to leave it available … Until now.
What I have for you today is my take on what is likely the biggest single news announcement AMAR has ever made. As TSR goes to press, the announcement hasn’t even been released – not in America, anyway – and won’t be for a few more hours. Fortunately, it was posted in Taiwan on Sunday. Equally fortuitous is my friendship with Mel Shriner, whom I met when I lived in Singapore. Mel follows the stock and used the 14-hour time difference to call and give me the heads up.
The news release announces a contract between Amarillo Biosciences and CytoPharm – a key subsidiary of the largest biopharmaceutical company in Taiwan. The relationship was formed to prove the efficacy of AMAR’s low-dose oral interferon regimen against influenza and hepatitis B.
Hepatitis B – known as “The Curse of the Chinese People” – is a major disease in Taiwan and China. Both governments have spent billions of dollars and committed even more to deal with this deadly disease. Under the terms of the agreement, many of those dollars – both hard and soft – will be directed at Amarillo Biosciences. CytoPharm will conduct (and pay for) all clinical trials, which is worth a few million dollars. It will also seek to obtain regulatory approvals in both Taiwan and China, which is a soft-dollar win beyond value. CytoPharm will also make payments to Amarillo upon reaching certain milestones – milestones that, ironically, CytoPharm itself will be achieving on Amarillo’s behalf. Pretty slick if you ask me.
The whole process will commence in 2007. But keep in mind: Unlike the news release itself, this will not be an overnight thing. It will take time to perform the trials and obtain the approvals. Also, even though the financial benefits are large, the real win comes from the free research dollars being committed to the project, as well as the connections to high-level regulatory persons. This much cash and those kinds of connections are two things Amarillo didn’t have – at least until now. The deal is analogous to having a Kennedy call the President of Harvard and personally request your admission to the university, do the studying for you, take the tests for you, grant you a large student loan and then pay for it. Like I said, it’s pretty slick.
It’s also very similar to the win/win deal AMAR CEO Dr. Joseph Cummins cut with a leading Middle Eastern pharmaceutical company to address Behçet’s disease in Turkey. It’s not a significant disease in the U.S., unless you happen to be one of the 15,000 to 20,000 Americans who suffer its debilitating effects. It is, however, a massive health problem in Turkey, where 300,000 persons are afflicted.
So here’s what Dr. Cummins did. First, he arranged for the pharmaceutical company in Turkey to perform all the necessary clinical trials to gain approval in Turkey. A year from now, when the trials are completed, Amarillo will have a wired-in customer that will pay it a royalty on every interferon tablet sold. As with today’s deal in Southeast Asia, 100% of the research costs in the Middle East will be borne by a third party. Second, Dr. Cummins intends to take the research results to the FDA for approval in the U.S. The beautiful irony is that here, because Behçet’s affects so few, it falls under the Orphan Drug Act. The designation is important because the Act is specifically designed to expedite FDA approval, as well as assist with related costs. I probably sounded like “The Ugly American” when I asked Dr. Cummins if the FDA would accept medical trials performed somewhere in Turkey. Loosely quoted he said, “They’d better. From the outset, we involved FDA folks in establishing the protocol to be used. Furthermore, we have an Internet link to Turkey (with real-time video) to monitor the tests and be certain the protocol is being performed ‘To the Letter.’”
This monitoring occurs several times each day. Medical and humanitarian considerations aside, I’m impressed that Dr. Cummins was able to use the smallness of the disease in one country to fast track its approval by one government, while using a corporation in another country where the disease is rampant to pay for all costs associated with the drug’s development.
So. this brings you up to speed on some key developments – all of which are positive and none of which have been reflected in the share price, which has pulled back without reason. As for negatives, the only one I’m aware of was of my own making. In the last regular Report, I mentioned I’d be meeting with a dozen of Amarillo’s key players in Beverly Hills. That was to occur at the Peninsula Club on Halloween. Long-story short, I did make it to the Beverly Hills Hilton where, at some point, I became enormously distracted and missed the meeting altogether.
As soon as the calendar allows for the smoke to clear, I’ll phone Dr. Cummins for a recap, then provide details of everything I missed in the next HotLine. Until then, put the details aside and take a long look at the Big Picture … the one that juxtaposes our Texas micro-cap against the world-class players who have involved themselves in every aspect of its operations. The comparison is profound.
On the Board of Directors, it has, Thomas D’Alonzo, former president of Glaxo Smith Kline (NYSE:GSK); plus a room full of M.D.s, Ph.D.s and wealthy professional private investors like Thomas Ulie, CEO of First Island Capital in Seattle. Amarillo’s mentor and largest stockholder is Hayashibara, Japan’s largest biopharmaceutical company and, according to Fortune magazine, one of the world’s largest privately held companies. The law firm of Hance, Scarborough, Woodward & Weisbart has been retained to represent AMAR in government matters. Kent Hance, a senior partner in that firm and the man who once beat George Bush in a congressional race, is especially close to AMAR. Hance is also the new Chancellor of Texas Tech University, where he presides over three campuses, 31,000 students, 459 doctors and millions in State of Texas grants.
There’s also Manfred Beilharz, Ph.D., who heads a Nobel Prize-winning School at the University of Western Australia. He’s working feverishly around the globe on a series of clinical trials specifically designed to prove the efficacy of oral interferon in various animals. At the June stockholders meeting, he said that, when his paper gets published – probably in either Nature or Science – his School will get another Nobel Prize, he will be famous and Amarillo’s stockholders will be rich. He said this half jokingly – but only half.
We’ve also got Dr. Claus Martin, who from everything I’ve read is THE physician to Europe’s jet set and SE Asia’s elite – some of whom are royalty. Cumulatively, Dr. Martin and his international entourage’s 2006 investment in AMAR stock was about $1.5 million. That’s a sizeable figure for private finance, but his contacts on both continents are probably more valuable than his cash. For 2007, Dr. Martin will embark on a number of trips to guarantee his investment.
Point of fact: In today’s CytoPharm release, Dr. Martin was identified as “Special Consultant” to AMAR and was quoted as saying, “The clinical data generated will provide invaluable assistance in our efforts to bring low-dose oral interferon into a number of countries with whom we have been holding a number of discussions, including Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia.”
One other point: Never mind the 29 patents, or the $30 million invested in the technology, or the new money being invested in the Turkish studies, or the even newer money associated with this morning’s release out of Taiwan. Instead consider all the NYSE-traded companies out there with market caps in the hundreds and hundreds of millions – companies that would kill for the kind of tight-knit international investor network that Amarillo, presently valued at just $14 million, already enjoys.
Virtually everyone listed above came to the table in 2006 and they’re working for little to nothing, trading their clout for stock or the simple opportunity to prove Amarillo right about oral interferon. So, ask yourself: What does this say about the Company’s future? What does it say about the Future of the Company’s stock? My answer? BUY more shares – and hold onto them tight.
As always, thank you for subscribing.
Greetz
xTRADERx
Amarillo Biosciences (NASDAQ/BB: AMAR): $0.63
Those of you who prefer the HotLine audio version over the e-mail transcript may have noticed that there was no recording to correspond with the Interim Special Report featuring ICRD. This was intentional. Since the Report was not scheduled, no one would have known to call. Moreover, I felt that the information from the Oct. 25 recording featuring Amarillo Biosciences held a good deal of value, so I wanted to leave it available … Until now.
What I have for you today is my take on what is likely the biggest single news announcement AMAR has ever made. As TSR goes to press, the announcement hasn’t even been released – not in America, anyway – and won’t be for a few more hours. Fortunately, it was posted in Taiwan on Sunday. Equally fortuitous is my friendship with Mel Shriner, whom I met when I lived in Singapore. Mel follows the stock and used the 14-hour time difference to call and give me the heads up.
The news release announces a contract between Amarillo Biosciences and CytoPharm – a key subsidiary of the largest biopharmaceutical company in Taiwan. The relationship was formed to prove the efficacy of AMAR’s low-dose oral interferon regimen against influenza and hepatitis B.
Hepatitis B – known as “The Curse of the Chinese People” – is a major disease in Taiwan and China. Both governments have spent billions of dollars and committed even more to deal with this deadly disease. Under the terms of the agreement, many of those dollars – both hard and soft – will be directed at Amarillo Biosciences. CytoPharm will conduct (and pay for) all clinical trials, which is worth a few million dollars. It will also seek to obtain regulatory approvals in both Taiwan and China, which is a soft-dollar win beyond value. CytoPharm will also make payments to Amarillo upon reaching certain milestones – milestones that, ironically, CytoPharm itself will be achieving on Amarillo’s behalf. Pretty slick if you ask me.
The whole process will commence in 2007. But keep in mind: Unlike the news release itself, this will not be an overnight thing. It will take time to perform the trials and obtain the approvals. Also, even though the financial benefits are large, the real win comes from the free research dollars being committed to the project, as well as the connections to high-level regulatory persons. This much cash and those kinds of connections are two things Amarillo didn’t have – at least until now. The deal is analogous to having a Kennedy call the President of Harvard and personally request your admission to the university, do the studying for you, take the tests for you, grant you a large student loan and then pay for it. Like I said, it’s pretty slick.
It’s also very similar to the win/win deal AMAR CEO Dr. Joseph Cummins cut with a leading Middle Eastern pharmaceutical company to address Behçet’s disease in Turkey. It’s not a significant disease in the U.S., unless you happen to be one of the 15,000 to 20,000 Americans who suffer its debilitating effects. It is, however, a massive health problem in Turkey, where 300,000 persons are afflicted.
So here’s what Dr. Cummins did. First, he arranged for the pharmaceutical company in Turkey to perform all the necessary clinical trials to gain approval in Turkey. A year from now, when the trials are completed, Amarillo will have a wired-in customer that will pay it a royalty on every interferon tablet sold. As with today’s deal in Southeast Asia, 100% of the research costs in the Middle East will be borne by a third party. Second, Dr. Cummins intends to take the research results to the FDA for approval in the U.S. The beautiful irony is that here, because Behçet’s affects so few, it falls under the Orphan Drug Act. The designation is important because the Act is specifically designed to expedite FDA approval, as well as assist with related costs. I probably sounded like “The Ugly American” when I asked Dr. Cummins if the FDA would accept medical trials performed somewhere in Turkey. Loosely quoted he said, “They’d better. From the outset, we involved FDA folks in establishing the protocol to be used. Furthermore, we have an Internet link to Turkey (with real-time video) to monitor the tests and be certain the protocol is being performed ‘To the Letter.’”
This monitoring occurs several times each day. Medical and humanitarian considerations aside, I’m impressed that Dr. Cummins was able to use the smallness of the disease in one country to fast track its approval by one government, while using a corporation in another country where the disease is rampant to pay for all costs associated with the drug’s development.
So. this brings you up to speed on some key developments – all of which are positive and none of which have been reflected in the share price, which has pulled back without reason. As for negatives, the only one I’m aware of was of my own making. In the last regular Report, I mentioned I’d be meeting with a dozen of Amarillo’s key players in Beverly Hills. That was to occur at the Peninsula Club on Halloween. Long-story short, I did make it to the Beverly Hills Hilton where, at some point, I became enormously distracted and missed the meeting altogether.
As soon as the calendar allows for the smoke to clear, I’ll phone Dr. Cummins for a recap, then provide details of everything I missed in the next HotLine. Until then, put the details aside and take a long look at the Big Picture … the one that juxtaposes our Texas micro-cap against the world-class players who have involved themselves in every aspect of its operations. The comparison is profound.
On the Board of Directors, it has, Thomas D’Alonzo, former president of Glaxo Smith Kline (NYSE:GSK); plus a room full of M.D.s, Ph.D.s and wealthy professional private investors like Thomas Ulie, CEO of First Island Capital in Seattle. Amarillo’s mentor and largest stockholder is Hayashibara, Japan’s largest biopharmaceutical company and, according to Fortune magazine, one of the world’s largest privately held companies. The law firm of Hance, Scarborough, Woodward & Weisbart has been retained to represent AMAR in government matters. Kent Hance, a senior partner in that firm and the man who once beat George Bush in a congressional race, is especially close to AMAR. Hance is also the new Chancellor of Texas Tech University, where he presides over three campuses, 31,000 students, 459 doctors and millions in State of Texas grants.
There’s also Manfred Beilharz, Ph.D., who heads a Nobel Prize-winning School at the University of Western Australia. He’s working feverishly around the globe on a series of clinical trials specifically designed to prove the efficacy of oral interferon in various animals. At the June stockholders meeting, he said that, when his paper gets published – probably in either Nature or Science – his School will get another Nobel Prize, he will be famous and Amarillo’s stockholders will be rich. He said this half jokingly – but only half.
We’ve also got Dr. Claus Martin, who from everything I’ve read is THE physician to Europe’s jet set and SE Asia’s elite – some of whom are royalty. Cumulatively, Dr. Martin and his international entourage’s 2006 investment in AMAR stock was about $1.5 million. That’s a sizeable figure for private finance, but his contacts on both continents are probably more valuable than his cash. For 2007, Dr. Martin will embark on a number of trips to guarantee his investment.
Point of fact: In today’s CytoPharm release, Dr. Martin was identified as “Special Consultant” to AMAR and was quoted as saying, “The clinical data generated will provide invaluable assistance in our efforts to bring low-dose oral interferon into a number of countries with whom we have been holding a number of discussions, including Thailand, Brunei, Myanmar, the Philippines, Malaysia, Singapore and Indonesia.”
One other point: Never mind the 29 patents, or the $30 million invested in the technology, or the new money being invested in the Turkish studies, or the even newer money associated with this morning’s release out of Taiwan. Instead consider all the NYSE-traded companies out there with market caps in the hundreds and hundreds of millions – companies that would kill for the kind of tight-knit international investor network that Amarillo, presently valued at just $14 million, already enjoys.
Virtually everyone listed above came to the table in 2006 and they’re working for little to nothing, trading their clout for stock or the simple opportunity to prove Amarillo right about oral interferon. So, ask yourself: What does this say about the Company’s future? What does it say about the Future of the Company’s stock? My answer? BUY more shares – and hold onto them tight.
As always, thank you for subscribing.
Greetz
xTRADERx
So sah es damals aus, als stockreport.de sich Amarillo vorgenommen hat!
Schaut euch den Januar 2006 an.
Bei 40 Cent mit rund 1 Mio. Stücken ging es los!
und dann innerhalb von 2 Monaten auf 1,40 Euro!
Das waren Zeiten...
USA RT 0,90 USD
Antwort auf Beitrag Nr.: 25.746.035 von NextLevelTrader am 27.11.06 15:34:47coole Sache das der Kurs auch in Amerika mit über + 30 % in der ersten Handelsstunde gestartet ist - zeigt doch, das die ganze Sache auf gesunden Füssen steht.
Ein schönes WE @all.
Es sieht heftig danach aus, daß wir bald wieder den 1€ knacken werden.
. Viel Glück an alle Investierte.
. Viel Glück an alle Investierte.
Wow, so langsam geht die Party richtig los!
In den USA hat Amar noch mal richtig Dampf gemacht! Schluss bei 0,97USD. Da kommt Freude auf.
In den USA hat Amar noch mal richtig Dampf gemacht! Schluss bei 0,97USD. Da kommt Freude auf.
Antwort auf Beitrag Nr.: 25.742.121 von RiseTrade am 27.11.06 10:55:38
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| 0,00 | |
| -1,20 | |
| -9,09 | |
| +2,86 | |
| -10,53 | |
| +8,33 | |
| 0,00 | |
| -50,00 | |
| -98,00 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 227 | ||
| 81 | ||
| 52 | ||
| 51 | ||
| 50 | ||
| 48 | ||
| 41 | ||
| 36 | ||
| 36 | ||
| 36 |
